Seattle-based startup Iridius has secured $8.6 million in seed funding to address a critical challenge facing companies in highly regulated sectors: artificial intelligence projects that never make it to production due to compliance obstacles. The company, founded by former Microsoft executives alongside talent from Amazon and OpenAI, is developing technology to automate regulatory compliance within AI systems.

Companies operating in regulated sectors like pharmaceuticals invest heavily in AI development, but much of this work fails to reach deployment because of stringent compliance, validation, and audit requirements that govern their operations. Iridius aims to solve this bottleneck by converting regulatory requirements and corporate policies into executable code, enabling automatic compliance enforcement during AI system operation rather than relying solely on post-implementation documentation. The platform also automatically records agent actions for audit purposes.

The funding round was spearheaded by Chalfen Ventures, with additional participation from Osage Venture Partners, Accenture Ventures, and Rock Yard Ventures. Accenture serves a dual role as both investor and strategic partner, collaborating with Iridius and potential
pharmaceutical clients to pinpoint opportunities where compliance automation can yield the greatest impact throughout the drug development process.

While the startup’s current concentration is on life sciences and pharmaceutical companies, the leadership team envisions expanding across other regulated industries in the future.

CEO and co-founder Mike Kropp, who accumulated 21 years of experience in engineering and product leadership at Microsoft before joining AWS, explained that the founding team initially approached former Microsoft colleagues with a broader concept of compliance infrastructure for enterprise AI applications. Initially, the idea generated little interest, as AI compliance wasn’t viewed as a priority concern.

However, by July of the previous year, the landscape had shifted dramatically. Microsoft began connecting the startup with major pharmaceutical customers who were experiencing a common frustration: AI pilot programs were advancing to the brink of production deployment before compliance requirements halted progress.

Kropp highlighted the massive scale of compliance demands in the pharmaceutical sector, noting that prospective customers allocate $1.5 billion annually to compliance efforts and must manage 70,000 internal standard operating procedures that require alignment with external regulatory frameworks.

Kropp established Iridius in 2024 alongside co-founder Alistair Lowe-Norris, a Microsoft veteran of 23 years who previously held the position of chief change officer under CEO Satya Nadella and now serves as Iridius’s chief product and responsible AI officer.

The leadership roster includes Mark Turley as co-founder, CFO and COO, previously leading accounting and financial operations at Highspot; Peter Larsen as chief technology officer, joining from AWS where he was a senior manager of solution architecture; Spencer Bentley as AI technical fellow, based in the U.K. and working as an OpenAI contractor since 2021; and Laura McFadden as VP of go-to-market and strategy, bringing finance experience from Amazon’s healthcare and consumer devices divisions.

Clark Golestani, former CIO and president of emerging businesses at Merck, joined the board last October following an industry event meeting with Kropp. The company has also assembled an advisory team including former CIOs from Alexion, Medtronic, Pfizer, Bayer, and Johnson & Johnson R&D, alongside Microsoft and other technology executives.

Currently, Iridius employs 11 people, predominantly based in the Seattle region.

The platform consists of two primary components: a knowledge engine that deconstructs regulations rule-by-rule and maintains them in a database accessible to AI agents in real time, and a solution factory that leverages these rules to assist customers in designing, building, and integrating AI workflows with existing enterprise systems.

Kropp emphasized that Iridius differentiates itself by embedding compliance directly into AI workflow execution rather than monitoring from an external vantage point. The company views established technology platforms like Veeva Systems, the leading software provider in life sciences, as integration opportunities rather than competitive threats.

While Iridius hasn’t yet launched commercially, the company has finalized a co-development agreement with one pharmaceutical customer and is engaged in discussions with others. The funding will support hiring initiatives, particularly expanding the AI engineering team.